Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
  Report  
Real-time Quote. Real-time Tradegate - 05/24 12:02:51 pm
66.525 EUR   +0.45%
05/23Why the world needs more than one Ebola vaccine
RE
05/23SANOFI : /Lexicon diabetes therapy gets PDUFA date
AQ
05/22SANOFI : FDA to review Zynquista™ (sotagliflozin) as potential..
PR
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Sanofi: Tests Show Zaltrap Improves Colorectal Cancer Survival Rate

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/08/2012 | 07:44am CEST

French drug company Sanofi SA (>> SANOFI) Monday said results from the pivotal Phase III Velour study evaluating Zaltrap showed improvement in overall survival rate to colorectal cancer.

MAIN FACTS:

- Sanofi said the Journal of Clinical Oncology published the results of the study evaluating Zaltrap effects.

- In the Velour trial evaluating metastatic colorectal cancer patients previously treated with an oxaliplatin-containing regimen, Zaltrap in combination with the Folfiri chemotherapy regimen (5-fluorouracil, leucovorin, irinotecan) showed a statistically significant improvement in overall survival, progression-free survival, and the overall tumor response rate versus placebo plus Folfiri.

- The Velour data supported the regulatory approval of Zaltrap by the U.S. Food and Drug Administration (FDA) on August 3, 2012 after a Priority Review.

- Zaltrap is under review at the European Medicines Agency and other regulatory agencies worldwide, Sanofi says.

-Write to Inti Landauro at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
Stocks mentioned in the article
ChangeLast1st jan.
SANOFI 0.82% 66.51 Delayed Quote.-8.39%
SANOFI 0.48% 66.52 Real-time Quote.-7.89%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
10:30aSANOFI : Amgens Repatha gets EU cardio risk reduction label
AQ
08:22aSANOFI : and Swansea collaborate on UK`s first diabetes centre of excellence
AQ
05/23Why the world needs more than one Ebola vaccine
RE
05/23SANOFI : FDA to review Zynquista (sotagliflozin) as potential treatment for type..
AQ
05/23SANOFI : House approves P1.161-billion supplemental budget for Dengvaxia vaccine..
AQ
05/23SANOFI : House panel okays P1.16-billion fund for Dengvaxia vaccinees' needs
AQ
05/23SANOFI : /Lexicon diabetes therapy gets PDUFA date
AQ
05/22SANOFI : Nograles backs DOH on full refund of Dengvaxia expenditure
AQ
05/22NUCANA : Announces Appointment of Cyrille Leperlier to its Board of Directors
AQ
05/22SANOFI : Russia and France to build business bridges at SPIEF 2018
AQ
More news
News from SeekingAlpha
05/23High Rates And Inflation Could Pose A Systemic Risk To Biotech 
05/23NOVAVAX : All Eyes On Q1 2019 
05/22FDA accepts Sanofi's marketing application for oral T1D med Zynquista 
05/21New England Journal of Medicine publishes on Dupixent Phase 3 trials 
05/19Spotlight On Gambling Reset And Banking Bill 
Financials (€)
Sales 2018 35 175 M
EBIT 2018 8 585 M
Net income 2018 5 100 M
Debt 2018 14 885 M
Yield 2018 4,65%
P/E ratio 2018 15,95
P/E ratio 2019 14,95
EV / Sales 2018 2,77x
EV / Sales 2019 2,61x
Capitalization 82 721 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 77,0 €
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Ameet Nathwani Executive Vice President-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-7.89%96 788
JOHNSON & JOHNSON-11.45%331 111
PFIZER-1.16%210 409
NOVARTIS-6.94%200 805
ROCHE HOLDING LTD.-9.17%191 486
MERCK AND COMPANY3.87%159 185